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Abstract
Background—The past several decades have seen dramatic growth in empirically supported 
treatments for adolescent substance use disorders (SUDs), yet even the most well-established 
approaches struggle to produce large or long-lasting improvements. These difficulties may stem, in 
part, from the high rates of comorbidity between SUDs and other psychiatric disorders.
Method—We critically reviewed the treatment outcome literature for adolescents with co-
occurring SUDs and internalizing disorders.
Results—Our review identified components of existing treatments that might be included in an 
integrated, evidence-based approach to the treatment of SUDs and internalizing disorders. An 
effective program may involve careful assessment, inclusion of parents or guardians, and tailoring 
of interventions via a modular strategy.
Conclusions—The existing literature guides the development of a conceptual evidence-based, 
modular treatment model targeting adolescents with co-occurring internalizing and SUDs. With 
empirical study, such a model may better address treatment outcomes for both disorder types in 
adolescents.
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INTRODUCTION
Recently summarized estimates from several large-scale epidemiological studies of US 
youth reveal an 8% lifetime prevalence of alcohol use disorders and 2–3% prevalence of 
illicit drug use disorders (1). The increase in prevalence from ages 13 to 18 and the strong 
association between early substance use and later substance use disorder (SUD) 
development (2, 3) highlight adolescence as a key period for SUD interventions. Treatments 
targeting this age group have the potential to impact the entire lifespan. In 1997, Stanton and 
Shadish’s meta-analysis (4) lamented a “dearth of clinical trial-tested treatment options for 
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adolescent drug abusers” (p. 187). Fortunately, since then, the treatment outcome literature 
for adolescent SUDs has expanded dramatically. A recent review identified 45 experimental 
or quasi-experimental treatment studies and concluded that most empirically evaluated 
interventions “appear to be beneficial” (5). Psychosocial treatments receiving support from 
clinical trials fall into three general categories: cognitive behavioral therapy (CBT), 
motivational interviewing (MI), and family/systems approaches (FSA). Although 
intervention strategies and efficacies vary both across and within these categories (6), each 
has now reached a generally accepted level of empirical support for their use. Mutual-help 
approaches such as 12-step programs are also associated with improved outcomes among 
adolescents (7). These programs, however, are used less frequently among adolescents 
relative to adults, and their effectiveness among adolescents has received less empirical 
attention (8).
Despite the expansion of the treatment outcome literature, there remains room for 
improvement in at least two domains. First, the body of evidence from randomized clinical 
trials is still relatively small. This issue is particularly apparent in comparison with outcome 
studies for adult SUDs, which greatly outnumber adolescent treatment studies and include 
widely recognized, large-scale clinical trials such as Project MATCH and the COMBINE 
Study (9–13). Moreover, beyond the 45 adolescent outcome studies reviewed by Tanner-
Smith and colleagues, more than 20 review articles have been published, an arguably 
disproportionate amount of scholarly discourse, particularly given the lack of demonstrably 
powerful and effective treatment options (4–6, 14–32). Clearly, the field would benefit from 
more empirical treatment outcome research.
Second, there is consensus that treatment gains in empirically supported treatments, though 
meaningful, are insufficient (21). As Wetherill and Tapert (14) noted, there is still a “lack of 
highly effective interventions for addictive behaviors among youth” (p. 398). In part, this 
consensus reflects the relatively modest effect sizes found in existing controlled trials (21), 
which are likely due to a range of factors related to patient motivation, compliance, 
response, retention, and relapse. More broadly, the substantive impact of interventions may 
be uncertain given that “well-controlled research on long-term treatment effects of 
[adolescent] drug treatment is virtually nonexistent” (p. 70, emphasis added) (15), although 
at least some have concluded that, following treatment, “a return to drug use (or relapse) is a 
fairly common occurrence among adolescents” (p. 419) (18).
Taken together, these two key issues—the need for further empirical study and the relatively 
modest impact of current treatments—reflect the extent to which outcomes for adolescents 
with SUDs can and should be improved. These conclusions are not new. In the present 
critical review, we seek to focus not only on the limitations of the existing literature but also 
on how it suggests ways to increase treatment gains. In particular, we emphasize psychiatric 
comorbidity, with internalizing (i.e., mood and anxiety) disorders specifically, as a key target 
for efforts to improve outcomes for adolescents with SUDs, and we draw from the literature 
to propose a conceptual model on which integrated, evidence-based treatment might be 
based (33). Thus, the focus and innovative aspect of this manuscript is to suggest 
improvements in the treatment of adolescent SUDs in the context of co-occurring 
internalizing disorders. We begin by establishing the presence of co-occurring psychiatric 
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and SUDs in adolescence and then explore etiological mechanisms unique to SUDs and 
internalizing disorders. We then review and critique existing co-occurring treatment models 
that incorporate internalizing disorders and close with a theoretical model for the treatment 
of co-occurring SUDs and internalizing disorders.
REVIEW
Adolescent SUD treatment in the presence of co-occurring disorders
In adolescent SUDs, dual diagnosis, or the presence of other co-occurring psychiatric 
disorders, is more common than not (30, 31, 34, 35), and prior reviews have highlighted the 
need to understand and address these high rates of comorbidity (21). Common co-occurring 
problems include conduct disorder (CD), attention-deficit/hyperactivity disorder (ADHD), 
mood disorders, and trauma-related disorders and symptoms (30). Approximately 11 – 48% 
of adolescents with SUDs in community samples have co-occurring internalizing disorders, 
with depression co-occurring more commonly than anxiety disorders (36). Rates of 
internalizing co-occurrence are even higher in clinical samples (36). A recent study of health 
records, for example, found that 29% of male and 49% of female adolescent patients with 
SUDs had co-occurring mood disorders, whereas 9% and 19% of male and female patients, 
respectively, had co-occurring anxiety disorders (37). Co-occurring disorders are also 
associated with increased SUD symptom severity, and co-occurring disruptive disorders in 
particular are associated with less successful treatment completion (35, 38).
Etiological Mechanisms Specific to Co-Occurring Internalizing and Substance Use 
Disorders
Developing more effective treatment programs will require an understanding of the specific 
etiological mechanisms that produce comorbid symptoms, particularly if co-occurring 
internalizing symptoms operate differently from co-occurring externalizing symptoms in 
their relationships to the development of SUDs. Although not the focus of this review, 
externalizing disorders frequently co-occur with one another and with SUDs, and a body of 
empirical evidence has developed examining this covariation, its structure, and its etiology 
(39–44). Evidence to date indicates that it may not be the case that externalizing disorders 
tend to lead to substance abuse or that SUDs promote externalizing behavior but rather that 
SUDs and externalizing disorders result from shared etiological forces—whether genetic, 
environmental, or both. In the absence of integrated treatment or a focus on underlying 
etiological mechanisms, addressing one class of symptoms may not substantially affect 
symptoms of the other disorder.
Whereas less research has addressed the topic, co-occurrence between SUDs and 
internalizing disorders may result from differing developmental processes. O’Neil and 
colleagues (36) recently presented a review of research on SUDs and internalizing disorders. 
Integrating findings regarding comorbidity, risk relationships, and the tendency toward 
temporal precedence of internalizing symptoms over SUDs, these authors concluded that 
internalizing disorders may, in some cases, serve as an etiological pathway to SUDs in 
youth. As an example, Hussong and colleagues speculate that early childhood internalizing 
symptoms may result in interpersonal skills deficits as well as expectancies about drugs of 
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abuse, both of which may motivate substance use to cope with negative affect, thereby 
increasing use and risk for SUDs (45). While this perspective is enticing in that it implies 
that identifying and meliorating internalizing disorders early could prevent the eventual 
emergence of some SUDs, the literature suggests several major caveats to this proposal. As 
O’Neil and colleagues (36) note, “though the majority of the evidence supports a 
unidirectional model in which childhood internalizing disorders increase risk for later SUDs, 
there is also evidence that substance use disorders may increase risk for internalizing 
disorders, or that the association may be explained by common risk factors” (p. 111). 
Indeed, genetically informed research has revealed a complex web of interrelationships 
among internalizing disorders and SUDs (42). For example, there are both genetic and 
environmental correlations between depressive symptoms and alcohol use across 
adolescence, supporting the role of common risk factors (46).
Taken together, the reviewed literature suggests several conclusions regarding treatment of 
adolescents with SUDs and co-occurring internalizing disorders. First, dual diagnosis with 
internalizing disorders may be qualitatively different from dual diagnosis with externalizing 
disorders, indicating that unique treatment approaches may be needed. Second, although the 
possible etiological role of early internalizing disorders in adolescent SUDs suggests that 
treating primary internalizing symptoms holds promise in addressing some SUDs, doing so 
will likely be insufficient to fully prevent or treat all co-occurrence (47). Thus, integrated 
treatments, in which both disorders are targets of intervention are likely the best approach 
(31, 48). Fortunately, several integrated treatment options have been developed, and below, 
we review these psychotherapeutic approaches with a focus on how they might inform 
current evidence-based practice as well as the development of new interventions. We confine 
our review to psychosocial interventions but note the robust literature on effective 
psychopharmacologic treatments for adolescent internalizing disorders (49, 50), particularly 
in dually diagnosed populations (51, 52).
Existing treatments for adolescents with co-occurring suds and internalizing disorders
Several approaches have been developed for treatment of adolescents with SUDs and co-
occurring disorders (29–32). The Substance Abuse and Mental Health Services 
Administration (SAMHSA)’s National Registry of Evidence-based Programs and Practices 
(NREPP) lists 18 adolescent substance use treatment programs (53). Of these, 10 have 
evidence supporting their use in treating any type of co-occurring psychiatric disorders 
(Adolescent Community Reinforcement Approach, Chestnut Health Systems-Bloomington 
Adolescent Outpatient and Intensive Outpatient Treatment Model, Family Behavior Therapy, 
Family Support Network [which comprises 12-sessions of Motivational Enhancement 
Therapy/Cognitive Behavioral Therapy, a family component, and case management], 
Multidimensional Family Therapy, Multisystemic Therapy, Parenting with Love and Limits, 
Phoenix House Academy, The Seven Challenges, and Seeking Safety). Two other programs 
listed under co-occurring disorders, Moral Reconation Therapy and Trauma Affect 
Regulation: Guide for Education and Therapy (TARGET), are additionally recognized as 
beneficial in this context, although their impact on substance use or abuse has not yet been 
described in NREPP.
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Unfortunately, these treatments for co-occurring SUDs and psychiatric disorders share the 
limited efficacy and substantial relapse risk of other adolescent SUD interventions. As 
Hawkins (31) noted, despite the promise of some positive outcomes, “virtually all of the [co-
occurring treatment] models share modest reductions in symptoms, difficulties maintaining 
treatment gains, and high relapse rates” (p. 215). Given the high prevalence of co-occurring 
disorders, improving treatment approaches that impact co-occurring disorders therefore 
offers the potential for substantial improvement over the current status quo. Notably, greater 
empirical attention should be paid to the extent to which differing categories of co-occurring 
disorders—such as externalizing (i.e., attention-deficit/hyperactivity disorder, conduct 
disorder, oppositional defiant disorder) and internalizing disorders—might necessitate 
different approaches to intervention (31). That is, not all co-occurrence should be treated 
equally. Although recognition and exploitation of this issue has recently led to the 
development of an effective adolescent substance use prevention program targeting specific 
personality risk profiles (i.e., anxiety sensitivity, hopelessness, impulsivity, and sensation 
seeking) (54–56), further consideration in the treatment literature is needed as well.
There has been less attention focused on treatment programs targeting adolescents with co-
occurring SUDs and internalizing disorders (vs. externalizing). This gap is especially 
striking given the relatively stronger efficacy of treatments for internalizing disorders 
relative to those for externalizing disorders (36). Of the treatments listed in NREPP for co-
occurring disorders, only five (Adolescent Community Reinforcement Approach, Family 
Behavior Therapy, Phoenix House Academy, The Seven Challenges, and Seeking Safety) 
have been identified for use with teens with any internalizing disorders. Beyond these 
existing programs, research is also ongoing to develop treatments for adolescents with SUDs 
and internalizing disorders. For example, a search of the NIH RePORTER database 
(projectreporter.nih.gov/reporter.cfm) on March 11, 2014 for projects funded through NCI, 
NIAAA, NIDA, NIMH, SAMHSA, or the VA with the search terms adolescent, treatment, 
substance, AND [internalizing, trauma, depression, OR anxiety] revealed five interventions, 
at varying stages of development, targeting the co-occurrence of SUDs and post-traumatic 
stress disorder, major depressive disorder (or depressive symptoms), and general 
internalizing symptoms. These treatment programs and ongoing research projects represent 
important steps toward improving outcomes for adolescents, yet given the limited 
effectiveness of current approaches (31), the field may additionally benefit from a broader 
search for interventions. We now turn to specific treatment components of existing models 
which address co-occurring internalizing disorders.
CBT and behavioral therapies have been identified as strong approaches for co-occurring 
disorders treatment (30). Macgowan and Engle (19), for example, recommend the use of 
behavioral interventions when adolescents with SUDs present with comorbidity or greater 
symptom severity. Indeed, an integrated CBT has been developed specifically for 
adolescents with SUDs and suicidality (57). CBT’s strengths in the context of co-occurring 
internalizing disorders include its extensive body of support for efficacy in treating anxiety 
and depressive disorders. Goal-directed techniques such as role-playing and modeling, self-
monitoring of behavior outside the therapy session, challenging maladaptive beliefs, and 
conducting behavioral exposures or experiments have the potential to generalize across 
target behaviors. Contingency management strategies to reinforce abstinence and other 
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therapy compliance have emerged as promising behavioral components among adolescents 
as well (58), at least when combined with CBT or other evidence-based interventions (59).
The use of CBT in co-occurring internalizing disorders treatment is also supported by 
research among adults. For example, a meta-analysis found that both CBT and 
antidepressant medications modestly improved outcomes for both alcohol use and 
internalizing disorders among alcohol use disorder patients (60). Treatment gains were 
greater for CBT relative to medication and for anxiety over depressive symptoms. More 
recent adult studies provide additional evidence in support of CBT. A six-hour, group-
delivered CBT program for anxiety and anxiety-coping-related alcohol use decreased 
alcohol consumption—although not anxiety symptoms—among residential alcohol use 
disorder patients (61). Similarly, a group-based CBT for depression and depression-related 
substance use improved depressive and SUD symptoms in a quasi-randomized study of 
residential treatments (62). These findings are tempered, however, by the fact that, like 
adolescent interventions, adult co-occurring disorder treatments have generally had difficulty 
producing meaningful and replicable benefits (63).
Motivational Interviewing (MI) is a conceptually distinct approach that is frequently 
combined with CBT (64). The MI therapeutic style is intended to increase motivation to 
change behavior. It employs a non-confrontational and validating yet directive mode of 
discussion that strives to enhance desire and self-efficacy by aligning patients’ substance-
related goals with their broader values (65). In the absence of concrete skill building or 
interventions against internalizing symptoms, MI is unlikely to be sufficient on its own with 
co-occurring disorders (24, 30). However, motivation to change is clearly quite important in 
SUD treatment and should be a target in developing improved co-occurring disorders 
interventions.
Other treatment programs that draw from CBT, including Dialectical Behavior Therapy 
(DBT) and Seeking Safety (SS), have also been recommended for use in adolescents with 
co-occurring SUDs and other psychiatric problems. DBT was first developed for individuals 
with borderline personality disorder and has been extended to treat a range of other disorders 
(66–69). DBT conceptualizes substance abuse as a response to mood dysregulation, and it 
combines traditional CBT-based skills training with acceptance and mindfulness practices 
(30, 31). As Hawkins (31) notes, it holds promise for treating co-occurring mood and 
anxiety disorders. To date, however, we are not aware of any trials of DBT for adolescent 
SUDs with or without co-occurring internalizing disorders. Further evidence is therefore 
needed to evaluate its potential value in this population.
SS also draws from CBT and was developed specifically for individuals with comorbid 
SUDs and trauma-related conditions such as post-traumatic stress disorder (PTSD). Among 
adults, SS has received considerable empirical support in treating symptoms of both PTSD 
and SUD (70). As reviewed by Hawkins (31), strengths of SS for adolescent SUDs and 
PTSD treatment may include its use of integrated CBT skills development and emphasis on 
the interplay between substance use and coping with PTSD symptoms. It should be noted, 
however, that to our knowledge SS has only been found efficacious among adolescents in 
one small controlled trial (71).
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Finally, FSA interventions, incorporating parental training and monitoring skills, also hold 
promise for use with co-occurring disorders. As reviewed by Rowe (15), FSA treatments 
such as Multidimensional Family Therapy (MDFT) are efficacious in treating adolescent 
SUDs, and there are strong links between indices of parental functioning and a range of 
offspring problems. Studies employing rigorous, quasi-experimental designs have found 
strong evidence that environmental factors associated with parental functioning, including 
marital instability and teen childbirth, may causally increase their offspring’s propensities 
for not only SUDs but also internalizing and externalizing symptoms (72, 73). Thus, a truly 
effective co-occurring internalizing disorders treatment will likely require the involvement of 
family, perhaps including interventions to directly target parenting behaviors.
In sum, existing interventions targeting co-occurring SUDs and internalizing disorders have 
been shown to impact internalizing symptoms, although indirectly. None have directly 
addressed internalizing symptoms as a primary focus of the treatment. We conclude that new 
treatment programs can draw from components of existing efficacious treatments, with an 
emphasis on targeting possible mechanisms of change that might generalize across SUDs 
and internalizing disorders. This strategy is akin to a modularity approach to treatment, in 
which components common to multiple empirically supported treatments are identified and 
then applied as appropriate (74). Such an approach has been developed for a wide range of 
youth mental health concerns (75, 76). Although it has been recommended for use in this 
population, the limited current empirical support for modular interventions for SUDs and co-
occurring disorders has impeded its implementation (77).
Conceptual Model for Co-Occurring Internalizing Disorder Treatment
Drawing from the results of our review, we conclude by proposing a conceptual model for 
treating co-occurring internalizing and substance use disorders. The model is built on 
individual CBT but incorporates MI, FSA, contingency management, and, where applicable, 
psychopharmacological interventions. It is designed to guide empirically informed practice 
but should not be considered authoritative given the absence of sufficiently strong evidence.
Our conceptual proposal rests on three principles. First, comprehensive psychiatric and SUD 
assessment is necessary to tailor an effective integrated treatment. As reviewed above, there 
are likely multiple mechanisms through which SUDs may co-occur with internalizing 
disorders. Comprehensive assessment can generate an accurate clinical conceptualization of 
their interplay and help guide treatment targeting. Second, as recommended by Hawkins 
(31), interventions for SUD and internalizing disorders should be integrated into a single 
treatment program. We recommend an approach in which integrated treatment is tailored by 
combining selected therapeutic modules and in which adolescents receive full doses of the 
components (e.g., exposure-based therapy for anxiety disorders) thought necessary to 
meliorate their symptoms (75, 77). Third, treatment should be multi-faceted, with CBT, 
motivational, parental, and, where relevant, psychopharmacological components (78, 79). 
Previous reviews have noted that there are multiple critical targets for interventions in co-
occurring disorders (30), and our model assumes an interdisciplinary approach in which 
each of these components plays a meaningful role.
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Given the clinical necessity of understanding specific comorbidities and their interplay, we 
suggest an approach with three phases and two major decision points (Fig. 1). The first 
phase would be a formal diagnostic evaluation session with adolescents and their parent(s) 
or guardian(s) that employs a structured or semi-structured diagnostic interview (e.g., K-
SADS-PL (80)). After diagnoses are made, providers may determine that some adolescents 
may be best treated through other services (e.g., inpatient hospitalization).
For candidate adolescents, the second phase of the intervention can begin. First, medication 
for mood or anxiety disorders (e.g., sertraline) and SUDs (e.g., buprenorphine), where 
indicated, may be started. Second, adolescents can begin to provide weekly follow-up 
measures in order to evaluate progress regarding both substance use and internalizing 
symptoms. These assessments could include the Timeline Follow-Back for substance use, 
the Children’s Depression Rating Scale, and the Multidimensional Anxiety Scale for 
Children, in addition to weekly drug screens (81–83). To reinforce their attendance and 
negative drug screens, adolescents would receive contingency management, which may be 
particularly valuable for those adolescents with co-occurring conduct or defiance symptoms 
or who are otherwise less motivated for treatment. Third, this model extends the benefits of 
current cognitive behavioral and motivational enhancement therapies by allowing for up to 
four additional assessment sessions to fully conceptualize the interplay between 
internalizing disorder symptoms and substance related behaviors that may not emerge until a 
closer therapeutic alliance has been formed. One component of this assessment is a 
functional analysis in which close examination of the bidirectional relationship between 
triggers precipitating use (internal motives and external motives) and reinforcing 
consequences of use (both positive and negative) can be understood.
Next, patients could begin a third treatment phase, which would add final treatment 
components: modular individual CBT and parent training. Using the results of the functional 
analysis, specific treatment modules can be organized into interventions tailored to an 
individual adolescent’s co-occurring internalizing symptoms. These tailored interventions 
can be roughly grouped into tracks for co-occurring trauma-related symptoms, depression, 
and non-trauma anxiety, and their length can be determined at this time. Recognizing that 
effectively addressing both the internalizing and substance use disorders takes time, our 
model attempts to strike a balance between undue treatment length and sufficient treatment 
duration. Since most CBT trials for adolescent depression fall within the 12–20 session 
range, we suggest a maximum of 20 sessions of individual CBT in the third phase. However, 
given the dearth of research on the topic, future investigations or clinical experience may 
ultimately dictate otherwise. For trauma, treatment components from SS may be the ideal 
third phase approach. For depression, behavioral activation strategies (84), for example, 
might be modified to promote pro-social, non-substance-related activities. For other anxiety 
disorders, treatments may focus on behavioral exposures that include substance-relevant 
cues. Socially anxious adolescents who engage in substance use to meliorate their 
discomfort in social gatherings might benefit, for instance, from exposures to “party” stimuli 
that combine substance-related and social cues. Finally, the third phase would also begin 
parent training independent of the adolescent’s tracking. Recent research has found that 
contingency management approaches with parents can help improve adolescents’ long-term 
abstinence-related behaviors (85, 86).
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The proposed model for empirically informed intervention has advantages and 
disadvantages. Improving motivation for change has been identified as a key component in 
SUD treatment, and to the extent that internalizing symptoms are more distressing than are 
SUD symptoms, integrated treatments may see motivational gains if they can promise 
internalizing symptom relief. Additionally, in cases where internalizing symptoms are 
etiologically involved in the development of SUDs, secondary gain from the treatment of 
those internalizing symptoms may produce greater SUD symptom improvement (36). These 
potential benefits are offset by what may be substantial costs. Most notably, this approach 
would require greater time and resources than might some existing empirically supported 
treatments. Given that adolescent co-occurring disorders are associated with increased 
severity, however, it is likely that these individuals may require more intensive (and perhaps 
longer) treatments, and to the extent that this model could reduce relapse rates, it may prove 
financially beneficial in the long run.
Implications for future research
Consideration of our proposed model of integrated treatment should be tempered by the 
recognition that the empirical literature does not yet provide absolute recommendations for 
clinical practice. Existing gaps in the literature, however, provide key opportunities for 
future studies to clarify recommendations for clinicians. First, as described above, the 
existing body of randomized, controlled trials is not large, particularly when considering co-
occurring disorders. More trials, particularly well-powered trials using appropriate, active 
control conditions, will help resolve current uncertainty. Second, studies using dismantling 
designs and other systematic means of identifying mechanisms of change will provide 
insight into ways of improving existing interventions (87). They additionally may help in 
selecting treatment components for inclusion in a modular integrated treatment. 
Contemporary CBT packages for SUDs and co-occurring disorders often include a wide 
range of interventions, including self-monitoring, psychoeducation, refusal skills, cognitive 
restructuring, and contingency management (79). Randomized, controlled trials with 
dismantling designs could examine the impact of each intervention and thereby provide 
evidence that one or more serves as an essential ingredient.
Third, the intervention literature will benefit from developmentally informed research into 
causal factors that are implicated in both SUD and internalizing disorders. Although there is 
much observational research on SUDs in youth, third variable confounding, transactional 
interplay among personal and environmental factors, and differences in the onset timing of 
different disorders raise serious questions regarding the inferences that can be drawn from 
traditional etiological research, even when temporal precedence can be demonstrated (36). 
Given the challenges of untangling complex developmental pathways, quasi-experimental 
designs may be valuable in clarifying causal relationships and selecting potential targets for 
intervention (88). Comparisons of twins or siblings within families, for example, can provide 
strong tests of childhood environmental exposures (89–91). Additionally, children of twins 
or siblings designs can add similar methodological rigor when testing the roles of parenting 
factors shared by siblings in offspring development (92).
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Fourth, the present review and proposed model focused on a single SUD sub-group, 
adolescents with co-occurring internalizing disorders. Additional sources of variability 
among those needing treatment for SUDs also merit further consideration. Indeed, the co-
occurring internalizing disorders population itself is likely far from homogenous, with many 
adolescents carrying additional internalizing and externalizing disorders or other medical 
comorbidities that may have implications for treatment. Other individual differences across 
and within these subgroups should be addressed in future research as well. One estimate, for 
example, suggested that only 6% of adolescent SUD treatment trials have tested for 
moderation by ethnicity (93).
Finally, our model draws heavily from behavioral and CBT intervention techniques, which is 
consistent with recommendations from previous reviews of this area (19, 30). CBT is 
effective in treating a range of internalizing disorders and is increasingly recognized as an 
efficacious treatment for adolescent SUDs. Nevertheless, when other efficacious approaches 
are developed, they may be able to replace or augment CBT as the central psychotherapy 
component in an integrated treatment model. As Wetherill and Tapert (14) note, 
mindfulness-based interventions may provide an alternative to CBT, and further evidence 
will help determine their level of efficacy. If new and more powerful treatments for co-
occurring internalizing disorders are to be integrated and inclusive, they will rely upon 
advances in the etiological and treatment-outcome literatures to identify the most crucial 
targets and interventions.
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Figure 1. 
Conceptual model of integrated, family-inclusive CBT for adolescent SUDs and co-
occurring internalizing disorders. Phase III tracking (i.e., depression, non-trauma anxiety, 
and trauma tracks) would be determined by the extended assessment and should include 
modules as indicated in the functional assessment. CM = contingency management for 
retention and negative drug screens (patient) and adherence (parents and/or guardian).
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